These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [In vitro activity of ertapenem against strains isolated from diabetic foot infections].
    Author: Sotto A, Lemaire X, Jourdan N, Bouziges N, Richard JL, Lavigne JP.
    Journal: Med Mal Infect; 2008 Mar; 38(3):146-52. PubMed ID: 18191514.
    Abstract:
    OBJECTIVE: The authors aimed to evaluate the in vitro activity of ertapenem against bacterial strains isolated from diabetic foot infections (DFI). METHODOLOGY: All diabetic patients hospitalized for a first episode of DFI (stages 2 to 4, according to the International Working Group of Diabetic Foot Classification) were selected in the Nîmes University hospital between January 2005 to December 2005. MICs were determined using both E-test strips and dilution methods on bacterial strains isolated from foot samples. RESULTS: Two hundred and fifty-two bacteria (154 Gram-positive cocci including 94 Staphylococcus aureus, 80 Gram-negative bacilli with 56 Enterobacteriaceae, and 18 anaerobes) were studied. Ertapenem was active against all Streptococcus spp., Enterobacteriaceae, anaerobes, and also against 89.8% of methicillin-susceptible S. aureus isolates. However, this antibiotic was active only against 31.5% of Staphylococcus epidermidis, 21.8% of Enterococcus faecalis, and 15.8% of Pseudomonas aeruginosa. CONCLUSION: Our results indicate that ertapenem may be a useful agent to treat patients suffering from DFI after bacterial identification.
    [Abstract] [Full Text] [Related] [New Search]